INTRODUCTION

Chronic hepatitis C virus (HCV)
infection is a major health problem affecting more than 170 million infected individuals worldwide. Liver cirrhosis is a real threat in 2-35% of the patients after 20-25 years of chronic infection [1]. The classical treatment for HCV infection was the dual therapy with pegylated interferon (Peg-IFN) α-2a or -2b combined with the guanosine analog ribavirin giving sustained virologic response (SVR) rate of only about 50% [2]. A new era of direct acting antivirals (DAAs), with SVR rate of about 90%, has emerged. Multiple regimens with various combinations of these drugs, without the use of IFN, proved to be effective and well tolerated, even among patients with advanced liver disease [3] .
Despite the poor treatment outcome in patients with decompensated cirrhosis (Child-Pugh B/C) compared to patients with compensated cirrhosis (ChildPugh A), safety issues regarding the use of DAAs among those patients with the most advanced liver disease have arisen [4] . Successful treatment of patients with decompensated liver disease due to HCV has two potential benefits. First, it could result in resolution of complications of endstage liver disease and improve survival resulting in delisting patients awaiting liver transplantation. Second, perhaps successful treatment of HCV could result in better post-transplant outcomes [5] .
Decompensation is the presence of at least one complication of end-stage liver disease including but not limited to hepatic encephalopathy, ascites or bleeding from esophagogastric varices. [6] . The Model for End-stage Liver Disease (MELD) is a validated chronic liver disease severity scoring system that uses a patient's laboratory values for serum bilirubin, serum creatinine, and the international normalized ratio (INR). In patients with cirrhosis, an increasing MELD score is associated with increasing severity of hepatic dysfunction and the three-month mortality risk [7] . Baseline MELD score can predict the risk of hepatic decompensation during IFN and antiviral therapy helping the decision making in HCV patients with advanced liver cirrhosis [8] . Several studies revealed improving MELD score after DAAs therapy in some patients with advanced HCV-associated liver cirrhosis [9,10].
The aim of this work is to study if MELD score can be reliably used for prediction of response to treatment with DAAs in "difficult to treat" chronic HCV patients.
PATIENTS AND METHODS
A retrospective cohort study was conducted as a collaborate work between Tropical Medicine Department, Faculty of Medicine, Zagazig University and Viral Hepatitis Treatment Unit, Al Ahrar Teaching Hospital. Ninety-one patients who were selected and categorized as "difficult to treat" were included in this study. Their files were randomly selected from the follow up clinic -in Al Ahrar hospital-till the completion of sample size from July 2017 to January 2018. 
Exclusion criteria:
 Child C cirrhotic patients (Child score ≥ 10)  Platelet count < 50,000 /mm3  HCC, except 6 months after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI).  Extra-hepatic malignancy except after two years of disease-free interval.  Pregnancy or inability to use effective contraception.  Inadequately controlled diabetes mellitus (HA1C>9).
Methods:
Data of all patients were collected before treatment and after 12 weeks of the end of treatment. 
RESULTS
Ninety-one patients who were categorized as "difficult to treat" were included in this study. Their files were selected randomly from the follow up clinic till the completion of sample size from July 2017 to January 2018.
59.3% of patients were males and 40.7 % were females. The mean age was 53.52 (53.52 ± 8.48) years and 11% only had prior HCV treatment. AFP level was 23.90 ± 18.40 ng/ml and HCV RNA level was 6.35 ± 4.17 million IU/ml (Table  2) .
After treatment, MELD score improved in about 28.6% of patients, remained stable in 57.1 % and worsen in 14.3 % (Table 3 ).
There was no significant difference in the mean values of MELD score between patients with and without SVR before treatment and also after treatment (Table 4) .
MELD score was improved in 27.9% of patients who had SVR. Despite that 40% of patients without SVR showed improvement of their MELD scores. There were no significant differences between both groups regarding percentage of improved, stable and worsen cases (Table 5) .
MELD score"s mean was higher among patients with complications when compared with those without complications before and after treatment with significant statistical differences. The patient without complications showed highly significant decrease in their mean MELD after treatment, while patients with complications showed nonsignificant increase of their mean MELD score. Five patients (5.5%) were complicated by variceal bleeding (one case), hepatic encephalopathy grade 2 (one case) and HCC (one case) ( Table 6 ).
In patients without complications, MELD scores were improved in 30.2% and worsen in about 10.5%, while in patients with complications; MELD scores did not improve in any one and worsen in 80% with highly significant difference ( Table 7) . 
DISCUSSION
Chronic hepatitis C virus infection is a major health issue worldwide. It is the leading cause of liver-related morbidity and mortality in Egypt and one of the most common indications for liver transplantation [13] . Pretreatment predictors of benefit are needed to guide patient selection for therapy and, more importantly, identify a group of patients in whom therapy is useless and who should undergo liver transplantation and DAAs therapy post-transplantation [14].
This retrospective study was planned to find the value of MELD score to predict the response and complications after DAAs therapy in "difficult to treat" chronic HCV patients. In this study, before treatment, mean MELD score in patients who achieved SVR didn"t show significant difference when compared with patients who didn"t achieve SVR indicating that MELD score cannot be used as a predictor of response to DAAs. This result can be explained by the significant decrease in the mean MELD score in patients with SVR and the unchanged score of patients without SVR after treatment. This result is not matching with that of Carrillo et al. who reported that decompensated cirrhosis (CTP B/C) at baseline was associated with lower rates of virologic response compared with patients with less advanced cirrhosis (CTP A). Carrillo and his colleague put Child B/C patients in one group leading to decreased response rate of this group. In addition, 67% of Child B patients in that study had score 7 which is the nearest score to Child A making those to achieve high SVR rate near to that of Child A [15].
CONCLUSION
Baseline MELD score cannot predict the response to treatment of "difficult to treat" chronic HCV patients but can predict the occurrence of complications.
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